3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
62
Glioblastoma
52
Lung Neoplasms
49
Breast Neoplasms
46
Prostatic Neoplasms
39
Head and Neck Neoplasms
38
Squamous Cell Carcinoma of Head and Neck
33
Esophageal Neoplasms
30
Brain Neoplasms
28
Lymphoma
27
Gliosarcoma
27
Rectal Neoplasms
24
Hodgkin Disease
24
Pancreatic Neoplasms
22
Adenocarcinoma Of Esophagus
22
Central Nervous System Neoplasms
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Neoplasms
20
Lymphoma, Non-Hodgkin
17
Leukemia
17
Glioma
17
Burkitt Lymphoma
16
Sarcoma
15
Lymphoma, Large B-Cell, Diffuse
15
Lymphoma, Follicular
14
Carcinoma, Squamous Cell
14
Colorectal Neoplasms
13
Astrocytoma
13
Neoplasm Metastasis
12
Melanoma
12
Interventions
human papillomavirus vaccine, L1 type 16, 18
30
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
20
Papillomavirus Vaccines
9
Radiotherapy, Intensity-Modulated
4
Cisplatin
4
Blood Specimen Collection
4
fludarabine
3
Vaccines, Synthetic
3
Engerix-B
3
Cyclophosphamide
3
halofantrine
2
fludarabine phosphate
2
aldesleukin
2
Watchful Waiting
2
Vaccines
2
Patient Navigation
2
Paclitaxel
2
Light Coagulation
2
Interleukin-2
2
Imiquimod
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
Hepatitis A Vaccines
2
Fluorouracil
2
Electrocoagulation
2
Cetuximab
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
utomilumab
1
polyphenon E
1
infigratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Papillomavirus Infections
×
Radiotherapy
×
Clear all
NCT02258659
2024-09-24
OPTIMA
University of Chicago
Phase 2
Completed
62 enrolled
13 charts